The global Parkinson’s Disease Treatment Market was valued at $5.37 billion in 2023 and is projected to reach $8.75 billion by 2032, with a CAGR of 5.57% from 2024 to 2032. Rising cases, advanced treatments like deep brain stimulation, and healthcare infrastructure improvements drive market growth.

Parkinson’s disease is a rapidly growing neurological disorder, with traditional medications like levodopa being primary treatments. Deep brain stimulation (DBS) is increasingly accessible, with over 25,000 procedures in the US in 2023. Ongoing research and new programs aim to improve long-term patient outcomes despite high therapy costs.

Carbidopa-levodopa holds over 30% market share, while dopamine agonists show the fastest growth rate in Parkinson’s disease treatment. Retail sales dominate with a 61% market share, while hospitals are expected to have a faster CAGR from 2024 to 2032, offering specialized treatments.

North America led the market in 2023 with a 39% share, driven by top-notch healthcare facilities and R&D investments. The Asia Pacific region is expected to experience the fastest growth rate due to increased healthcare spending and awareness of neurological conditions.

Recent developments include new non-invasive neuromodulation therapy and cell-based therapy for Parkinson’s Disease. The report offers unique insights like Parkinson’s incidence metrics, treatment trends index, drug production analysis, healthcare spending distribution, and patient care burden metrics.

SNS Insider is a leading market research and consulting agency providing crucial market data and insights for informed decision-making. With a variety of research techniques, including surveys and focus groups, we aim to empower clients with accurate and current market information.

Read more at GlobeNewswire: Parkinson’s Disease Treatment Market Projected to Reach